Imatinib mesylate is a tyrosine kinase inhibitor with preferential activity toward the bcr-abl fusion protein of chronic myelogenous leukemia (CML).
1 Imatinib mesylate is also active against a limited number of other tyrosine kinases, including c-kit, PDGFRa and PDGFRb. 2 Significant clinical activity has been demonstrated in diseases in which these tyrosine kinases play a major role, including a variety of myeloproliferative disorders such as the hypereosinophilic syndromes.
3 Currently, we report on a patient with an atypical myeloproliferative disorder and a novel balanced translocation who had a dramatic clinical response to imatinib mesylate. The specific target in this patient is unknown.
The patient is a 63-year-old male who presented in May 2004 with bone pain, early satiety and massive splenomegaly. The white blood count (WBC) was 29 000/mm 3 , the hemoglobin (HGB) was 11.3 gm/dl and the platelet count was 1 800 000/mm 3 . An initial bone marrow aspirate was dry and the biopsy was insufficient. The patient was placed on hydroxyurea, however, his platelet count continued to increase and the patient was referred to us for evaluation. In June 2004, the spleen was 19 cm below the left costal margin. The WBC was 16 700/mm 3 , with 52% neutrophils, 5% bands, 6% metamyelocytes, 2% myelocytes, 3% blasts, 9% monocytes, 14% lymphocytes, 4% eosinophils, 5% basophils and two nucleated red blood cells. The HGB was 10.4 g/dl and the platelet count was 1 627 000/ mm 3 . Bone marrow aspiration was aspiculate with numerous platelet clumps. The myeloid series was slightly left-shifted (7% blasts) but with normal morphology and full maturation. The M:E ratio was 4.9:1. Biopsy showed the bony trabeculae were osteosclerotic, and the matrix of the marrow was hypocellular with loose, pseudomyxoid fibrosis and markedly dilated sinusoids. The megakaryocytes were increased in number and demonstrated cytologic atypia. There was a diffuse mild increase in reticulin fibers. Flow cytometric analysis demonstrated 5% blasts with the following phenotype: CD4, CD13, CD33, CD34, CD117 and HLA-DR. The interpretation was chronic myeloproliferative disorder, best classified as idiopathic myelofibrosis at the early fibrotic stage. Molecular (reverse transcriptase-polymerase chain reaction) and fluorescent in situ hybridization tests for bcr-abl were negative. Cytogenetics demonstrated 46,XY,t(1;3)(q31;q23) in 20 of 20 metaphases.
Anegrelide was added, however, the patient developed high fevers (1031), tachycardia, and myocardial infarction, and the drug was discontinued. The patient's platelet count continued to increase up to 2 600 000/mm 3 . Busulfan and cytarabine were tried empirically. The platelet count decreased after each treatment, but then rebounded sharply. The spleen remained enlarged at 14 cm below the left costal margin. In October 2004, 400 mg imatinib mesylate was started. After 1 month, imatinib mesylate was increased to 800 mg daily. Owing to moderately severe facial edema, imatinib mesylate was then lowered to 600 mg daily. Over the past 2 years, the patient has been well, except for mild facial edema and generalized hypopigmentation. On some occasions, the patient's counts increased and imatinib mesylate was increased to 800 mg for short periods of times. Since the initiation of imatinib mesylate, the patient's WBC has ranged from 11 100 to 18 100/mm 3 , the HGB from 10.2 to 11.1 gm/dl and the platelet count from 422 000 to 665 000/mm 3 . The patient has had complete resolution of splenomegaly. He declined repeat bone marrow examinations, but peripheral blood cytogenetics still demonstrate t(1;3)(q31;q23). A JAK2 V617F mutation was not detected.
The current patient has an atypical myeloproliferative disorder with a novel translocation, t(1;3)(q31;q23), and a clinical response to imatinib mesylate. In contrast to other imatinib mesylate responsive disorders such as CML, where imatinib mesylate frequently results in a cytogenetic and/or molecular remission, this patient has persistent cytogenetic abnormalities despite dramatic clinical improvement (stabilization of blood counts and resolution of splenomegaly).
Although imatinib mesylate is most active against CML, a variety of myeloproliferative disorders with activated imatinibsensitive tyrosine kinases also respond.
3 These include cases of atypical CML in which activation of PDGFRa occurs through the reciprocal translocation t(4;22)(q12;q11) and BCR-PDGFRa fusion, 4 and cases of hypereosinophilic syndrome with activation of either PDGFRa through an interstitial deletion of 4q12 and FIP1L1/PDGFRa fusion 5 or reciprocal translocation involving chromosome 5q33 and fusion of PDGFRb with a variety of partners. 6 In general, these patients respond to low doses of imatinib mesylate, ranging from 100 to 400 mg/day. Responses of myelofibrosis to imatinib mesylate have been mixed. Tefferi treated 23 patients with imatinib mesylate at a starting dose of 400 mg daily.
7 Most patients were unable to tolerate this treatment owing to myelosuppression, and no significant clinical responses were seen. On the other hand, of 18 patients treated at the MD Anderson Cancer Center, 72% experienced objective improvements in clinical or hematologic parameters. 8 Median duration of response and cytogenetic abnormalities were not noted in the latter report.
Our patient has a novel translocation, t(1;3)(q31;q23), which to our knowledge has not been previously reported in patients with myeloproliferative disorders. Although a number of genes are located at these sites, none are known targets of imatinib mesylate. Alternatively, it is possible that inhibition of c-kit (which was present on his blasts) could be the underlying mechanism of the durable response in this patient. Invasive aspergillosis (IA) is a leading cause of infection-related mortality in hematologic patients, with death rate ranging from 50 to 90%.
1
The reason for this extremely poor outcome is because of the difficulties in a timely and undoubted diagnosis, which still relies on a very high degree of suspicion. The current diagnostic tools are limited by invasiveness, slowness, relative insensitiveness, lack of standardization and unpredictable kinetics. 2 The most widely studied test, Galctomannan antigenemia (GM), has been demonstrated to be highly variable in performance, with sensitivity ranging between 29 and 100%, and is affected by several factors related either to the fungus or to the host.
2 Furthermore, the detection of Aspergillus DNA through polymerase chain reaction (PCR) is still hampered by the difficulties in understanding the fungal DNA release and kinetics other than by technical barriers.
2 For all these reasons, establishing an early diagnosis of IA remains a challenge.
1,2
Recent studies have shown that adaptive immunity contributes to the host defense against Aspergillus species.
3 In the murine model of IA, mice resistant to the infection produce a high pulmonary level of T helper1 (T H 1) cytokines, whereas mice with a high level of T helper2 (T H 2) cytokines suffer from disease progression. 4 In a human clinical setting, a study has measured the production of either interferon-g (IFN-g) or interleukin-10 (IL-10) in culture supernatants of peripheral blood mononuclear cells (PBMCs) stimulated with Aspergillus antigens, showing that patients with high IFN-g/IL-10 ratio survive IA.
5 Moreover, the adoptive transfer of Aspergillusspecific IFN-g-producing T-cells (IFN-g-T H 1) has been reported to cure IA in allogeneic bone marrow transplant (alloBMT) patients.
6
To evaluate whether enumeration of Aspergillus-specific IFNg-T H 1 and Aspergillus-specific IL-10-producing T-cells (IL-10-T H 2) through an ex vivo enzyme-linked immunospot (ELISPOT) assay could improve the diagnosis and the clinical management of IA, we report the first clinical application of ELISPOT in a series of 10 hematologic patients with neutropenia and pulmonary infiltrates, including three of them with proven IA, as well as two healthy blood donors. ELISPOT has been performed on frozen peripheral blood samples, as described by Lalvani et al. 7 The study was approved by our institution review board. All patients gave their informed consent to the study. All patients were receiving antifungal prophylaxis with itraconazole 200 mg/b.i.d. when peripheral blood specimens were collected. PBMCs from either patients or healthy subjects were separated by using Ficoll-Hypaque gradient centrifugation (Linaris, Bettingen am Main, Germany) and then cultured in a 96-well polyvinylidene difluoride-bached plate coated with either anti-IFN-g or IL-10 monoclonal antibody (Mabtech, Nacka Strand, Sweden). Cells were stimulated with heatinactivated conidia, prepared from a patient's Aspergillus fumigatus isolate, or with a water-soluble cellular extract of Aspergillus fumigatus and with phytohemoagglutinin. A total of 1 Â 10 5 and 2.5 Â 10 4 cells/well were cultured in the IFN-g and IL-10 assay, respectively, for 16 h. All test conditions were carried out in triplicate and the results were considered positive if the number of spot-forming cells (SFC)/10 6 cells in Aspergillus antigen-stimulated wells was twofold higher than that in control wells (non-Aspergillus antigen-stimulated cells) and there were at least 20 spots. The assay was performed by one of the authors (PB), blinded to the patients' radiologic and clinical histories and personal identifiers, using an automated ELISPOT counter (AID-GmbH, Strassberg, Germany).
Patient 1 was a 59-year-old woman with acute myeloid leukemia (AML), presenting fever and an ovalar nodule surrounded by a halo of ground glass opacity (GG-O) in the left lung, detected at high-resolution computed tomography (HRCT) during neutropenia following induction chemotherapy (iCHT) (Figure 1b , 07/01/05). Cultural and molecular examination of blood, urine, feces and bronchoalveolar lavage fluid (BALf) were repeatedly negative for bacterial, fungal or viral pathogens. GM was negative either on serum or on BALf. Fever persisted despite vancomicine, meropenem and liposomal amphotericine B (L-amB) at 3 mg/kg/day. A second HRCT showed enlargement of the nodular opacity with unmodified GG-O. Serum GM was negative (Figure 1b , 07/06/05). The L-amB dose was increased to 5 mg/kg/day. A few days later, the patient became afebrile, concomitantly with full hematologic recovery. After 1 week, HRCT showed a slight reduction of both the GG-O and the nodular lesion, with cavitation and air crescent formation (Figure 1b , 07/14/05). The patient underwent a video-assisted thoracoscopic (VATS) resection of the pulmonary consolidation. Histological and immunohistochemical examination disclosed IA.
